MET and prostate cancer: Of note, the negative regulation of c-Met protein levels by FASN independent of the proteasome system has been previously reported in the DU145 prostate cancer cell line following the treatment with the FASN inhibitor, luteolin28, further indicating that downregulation of c-Met occurs via mechanisms that are ubiquitin-independent in cancer.